This study is testing a medication called VS-041 in people with heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart can pump blood normally, but it's too stiff to fill properly. The study aims to understand the safety and how well VS-041 is tolerated at different doses (high and low), compared to a placebo (an inactive pill). Researchers will also look at how the medication affects certain markers in your blood. You may be able to join if you are 50 years or older and have been diagnosed with HFpEF, with symptoms that are mild to moderate (NYHA Functional Class II or III). The study plans to enroll 42 participants.

Study design

This interventional study will involve 42 participants who will receive either a high dose of VS-041, a low dose of VS-041, or a placebo twice a day.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Researchers will monitor participants for adverse events and changes in blood markers from when they start the study until Day 28.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.